Osaka, Japan

Eiko Iguchi

This inventor holds 11 USPTO granted patents. Top assignee: Fujisawa Pharmaceutical Company, Ltd.. Active years: 1979-1989.


% Patents Active = 100.0

Average Co-Inventor Count = 9.8

ph-index = 5

Forward Citations = 56(Granted Patents)


Company Filing History:


Years Active: 1979-1989

Loading Chart...
11 patents (USPTO):Explore Patents

Title: Eiko Iguchi: Innovator in Peptide Research

Introduction

Eiko Iguchi is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of pharmacology through her innovative research and development of novel peptides. With a total of 11 patents to her name, Iguchi has established herself as a leading figure in her area of expertise.

Latest Patents

Among her latest patents, Iguchi has developed peptides that exhibit pharmacological activity. One of her notable inventions is a peptide with the formula: ##STR1## wherein R.sup.1 is hydrogen. Additionally, she has created another peptide that demonstrates enhanced pharmacological activity, represented by the formula: ##STR1## wherein R.sup.1 is hydroxyalkanoyl. These advancements highlight her commitment to improving therapeutic options in medicine.

Career Highlights

Eiko Iguchi is currently employed at Fujisawa Pharmaceutical Company, Ltd., where she continues to push the boundaries of peptide research. Her work has not only contributed to the scientific community but has also paved the way for new treatments in pharmacology.

Collaborations

Throughout her career, Iguchi has collaborated with esteemed colleagues, including Hatsuo Aoki and Hiroshi Imanaka. These partnerships have further enriched her research and expanded the impact of her inventions.

Conclusion

Eiko Iguchi's innovative work in peptide research has led to significant advancements in pharmacology. Her contributions, marked by 11 patents, reflect her dedication to improving healthcare through scientific innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…